ArticleFrontiers in pharmacology2022

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.

Tingting Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.